Positive Results from Human PK Study Assessing Orexo’s Intranasal Nalmefene Formulations for Opioid Overdose Reversal

Positive Results from Human PK Study Assessing Orexo’s Intranasal Nalmefene Formulations for Opioid Overdose Reversal

Publication date: Jun 30, 2020

Preliminary data indicate extensive and rapid absorption of OX125 across all formulations Positive results underline the applicability of Orexo’s novel intranasal drug delivery platform UPPSALA, Sweden, June 30, 2020 /PRNewswire/ — Orexo AB (publ. )

The study was a cross-over, comparative bioavailability study in healthy volunteers to assess nalmefene absorption from three development formulations of OX125, Orexo’s wholly-owned nasal nalmefene product, compared to a nalmefene intramuscular injection.

Preliminary results indicate extensive and rapid absorption across all three OX125 formulations as well as good tolerability, supporting the viability of OX125 as a rescue medication for opioid overdose.

Highly potent synthetic opioids, such as fentanyl, have become the leading cause of death following drug overdoses in the US with over 31,000 fatalities in 2018. 1 Like naloxone, nalmefene is an opioid antagonist that acts by blocking the effects of opioids at the opioid receptors.

The addressable market for OX125 and OX124 is large and growing as demand for easy to use, potent overdose reversal medication increases, not only for emergency staff and first responders, but also for opioid dependent patients, and as co-prescription for high-dose opioid pain patients.

The main market today is the American market for buprenorphine/naloxone products, where Orexo commercialize its lead product Zubsolv(R) for treatment of opioid use disorder.

About OX125 OX125 is a nasal nalmefene rescue medication under development by Orexo.

Naloxone is a full opioid receptor antagonist which reverses the effects of opioid agonists, including the life threatening respiratory depressant effects occurring in an opioid overdose.

Concepts Keywords
ADRs Naloxone
Antagonist Nalmefene
Bioavailability Tertiary alcohols
Blockade Euphoriants
Buprenorphine Opioid antagonists
CEO Morphinans
CET RTT
Cross Psychoactive drugs
Digital Drugs
Drug Delivery Opioids
FDA Space substance disorders
Fentanyl Nasal nalmefene product
Heroin Pharmaceutical product
Intramuscular Injection Pharmaceuticals digital therapies
Intranasal Drug delivery
LinkedIn Buprenorphine/naloxone
Mail Fentanyl
Mental Health
Naloxone
Nasal
Nasal Mucosa
Nasdaq Stockholm
Opioid
Opioid Addiction
Opioid Antagonist
Opioid Overdose
Opioid Receptor Antagonist
Opioids
OTCQX
Overdose
Pain
Pandemic
Pharmaceutical
Pharmaceuticals
Pharmacokinetic
Plasma
President
Product Demonstration
Receptors
Respiratory Depressant
SEK
STO
Sweden
Tolerability
Twitter
Uppsala
UPPSALA
USD
YouTube

Semantics

Type Source Name
drug DRUGBANK Nalmefene
drug DRUGBANK Nonoxynol-9
disease MESH development
drug DRUGBANK Fentanyl
disease MESH cause of death
drug DRUGBANK Naloxone
drug DRUGBANK Diamorphine
disease MESH substance use disorders
disease MESH suffering
disease MESH opioid addiction
disease MESH emergency
drug DRUGBANK Etoperidone
drug DRUGBANK Buprenorphine
drug DRUGBANK Coenzyme M
drug DRUGBANK Cefalotin

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *